BioWorld

Oct. 19, 2005

View Archived Issues

Sonus, Schering In Tocosol Paclitaxel Deal Worth $168M

After starting a pivotal trial last month, Sonus Pharmaceuticals Inc. now has secured a sweet deal for its cancer product Tocosol Paclitaxel, giving exclusive worldwide rights to Schering AG. (BioWorld Today) Read More

Genzyme Beats Estimates, CEO Reports Excellent' Third Quarter

Read More

Lorus' Shares Take Plunge On Phase III Virulizin Data

Read More

Kosan Stops Prostate Cancer Phase II After Interim Check

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More